G protein-coupled receptor kinase 2 promotes cardiac hypertrophy
暂无分享,去创建一个
T. Wieland | W. Koch | P. Most | H. Katus | J. Backs | E. Gao | P. Raake | H. Tscheschner | Eric Meinhardt | P. Schlegel | Ancai Yuan | Sarah M. Schumacher | J. Reinkober
[1] D. Sorriento,et al. Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy , 2015, Journal of Cardiovascular Translational Research.
[2] J. Moalem,et al. Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression. , 2014, Journal of the American College of Cardiology.
[3] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[4] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[5] W. Koch,et al. Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy , 2013, Front. Physiol..
[6] U. Haberkorn,et al. AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. , 2013, European heart journal.
[7] W. Koch,et al. Prodeath Signaling of G Protein–Coupled Receptor Kinase 2 in Cardiac Myocytes After Ischemic Stress Occurs Via Extracellular Signal–Regulated Kinase-Dependent Heat Shock Protein 90–Mediated Mitochondrial Targeting , 2013, Circulation research.
[8] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[9] S. Houser,et al. Cardiac G-Protein–Coupled Receptor Kinase 2 Ablation Induces a Novel Ca2+ Handling Phenotype Resistant to Adverse Alterations and Remodeling After Myocardial Infarction , 2012, Circulation.
[10] H. Rockman,et al. Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. , 2011, Journal of molecular and cellular cardiology.
[11] Mark A Sussman,et al. Myocardial AKT: the omnipresent nexus. , 2011, Physiological reviews.
[12] T. Matsui,et al. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. , 2011, Current pharmaceutical design.
[13] G. Dorn,et al. G Protein–Coupled Receptor Kinase 2 Activity Impairs Cardiac Glucose Uptake and Promotes Insulin Resistance After Myocardial Ischemia , 2011, Circulation.
[14] F. von Wegner,et al. The Inotropic Peptide &bgr;ARKct Improves &bgr;AR Responsiveness in Normal and Failing Cardiomyocytes Through G&bgr;&ggr;-Mediated L-Type Calcium Current Disinhibition , 2011, Circulation research.
[15] David M. Harris,et al. Level of G protein–Coupled Receptor Kinase-2 Determines Myocardial Ischemia/Reperfusion Injury via Pro- and Anti-Apoptotic Mechanisms , 2010, Circulation research.
[16] Cristina Murga,et al. The complex G protein‐coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets , 2010, British journal of pharmacology.
[17] S. Houser,et al. G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure , 2008, Circulation research.
[18] K. Griendling,et al. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.
[19] I. Shiojima,et al. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.
[20] G. Dorn,et al. Cardiac-Specific Ablation of G-Protein Receptor Kinase 2 Redefines Its Roles in Heart Development and &bgr;-Adrenergic Signaling , 2006, Circulation research.
[21] P. Penela,et al. Mdm2 is involved in the ubiquitination and degradation of G‐protein‐coupled receptor kinase 2 , 2006, The EMBO journal.
[22] T. Kozasa,et al. Snapshot of Activated G Proteins at the Membrane: The Gαq-GRK2-Gßγ Complex , 2005, Science.
[23] J. Molkentin,et al. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. , 2004, Biochemical and biophysical research communications.
[24] Jian Xu,et al. Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.
[25] M. Boerries,et al. Extracellular S100A1 Protein Inhibits Apoptosis in Ventricular Cardiomyocytes via Activation of the Extracellular Signal-regulated Protein Kinase 1/2 (ERK1/2)* , 2003, Journal of Biological Chemistry.
[26] E. Olson,et al. Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.
[27] R. Lefkowitz,et al. Regulation of G protein-coupled receptor signaling by scaffold proteins. , 2002, Circulation research.
[28] Robert J. Lefkowitz,et al. Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors , 2001, Nature Reviews Neuroscience.
[29] M. Caron,et al. Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by β-Adrenergic Receptor Kinase 1 , 2001, The Journal of Biological Chemistry.
[30] E. Lakatta,et al. Erratum: Culture and adenoviral infection of adult mouse cardiac myocytes: Methods for cellular genetic physiology (American Journal of Physiology - Heart and Circulatory Physiology (July 2000) 279:48 (H429-H436)) , 2000 .
[31] E. Lakatta,et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. , 2000, American journal of physiology. Heart and circulatory physiology.
[32] R. Penn,et al. Analysis of the human G protein-coupled receptor kinase 2 (GRK2) gene promoter: regulation by signal transduction systems in aortic smooth muscle cells. , 2000, Circulation.
[33] W. Koch,et al. Gβγ-dependent Phosphoinositide 3-Kinase Activation in Hearts with in Vivo Pressure Overload Hypertrophy* , 2000, The Journal of Biological Chemistry.
[34] W. Koch,et al. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. , 2000, The Journal of biological chemistry.
[35] D. Levy,et al. Why is left ventricular hypertrophy so predictive of morbidity and mortality? , 1999, The American journal of the medical sciences.
[36] J. Ross,et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] R. Lefkowitz,et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.
[38] Jeffrey Robbins,et al. A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.
[39] W. Koch,et al. Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.
[40] M. MacDonald,et al. Characterization of the G Protein-coupled Receptor Kinase GRK4 , 1996, The Journal of Biological Chemistry.
[41] R. Lefkowitz,et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. , 1995, Science.
[42] M. Böhm,et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.
[43] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.